 |
|
Decrease in Brain Serotonin 2 Receptor Binding in Patients With Major Depression Following Desipramine Treatment
A Positron Emission Tomography Study With Fluorine-18–Labeled Setoperone
Lakshmi N. Yatham, MBBS, FRCPC;
Peter F. Liddle, PhD, MBBS;
Joelle Dennie, MSc;
I-Shin Shiah, MD;
Michael J. Adam, PhD;
Carol J. Lane, MSc;
Raymond W. Lam, MD;
Thomas J. Ruth, PhD
Arch Gen Psychiatry. 1999;56:705-711.
Background The neuroreceptor changes involved in therapeutic efficacy of various antidepressants remain unclear. Preclinical studies have shown that long-term administration of various antidepressants causes down-regulation of brain serotonin 2 (5-HT2) receptors in rodents, but it is unknown if similar changes occur following antidepressant treatment in depressed patients. Our purpose, therefore, was to assess the effects of treatment with desipramine hydrochloride on brain 5-HT2 receptors in depressed patients using positron emission tomography (PET) and fluorine-18 (18F)–labeled setoperone.
Methods Eleven patients who met DSM-IV criteria for major depression as determined by a structured clinical interview for DSM-III-R diagnosis and suitable for treatment with desipramine were recruited. Ten patients underwent a PET scan before and another after 3 to 4 weeks of treatment with desipramine.
Results Eight of the 10 patients responded to desipramine treatment as indicated by more than 50% decrease in Hamilton Depression Rating Scale scores. Depressed patients showed a significant decrease in 5-HT2 receptor binding as measured by setoperone binding in frontal, temporal, parietal, and occipital cortical regions following desipramine treatment. The decrease in 5-HT2 receptor binding was observed bilaterally and was particularly prominent in frontal cortex.
Conclusions Depressed patients showed a significant reduction in available 5-HT2 receptors in the brain following desipramine treatment, but it is unknown if this change in 5-HT2 receptors is due to clinical improvement or an effect of desipramine that is unrelated to clinical status.
From the Divisions of Mood Disorders (Drs Yatham, Shiah, and Lam and Ms Dennie) and Schizophrenia (Dr Liddle and Ms Lane), Department of Psychiatry, and the TRIUMF Positron Emission Tomography Program (Drs Adam and Ruth), The University of British Columbia, Vancouver; and the Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (Dr Shiah).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: III. Actions in Models of Potential Antidepressive and Anxiolytic Activity in Comparison with Ropinirole
Millan et al.
J. Pharmacol. Exp. Ther. 2004;309:936-950.
ABSTRACT
| FULL TEXT
S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: I. Receptor Binding, Electrophysiological, and Neurochemical Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine
Millan et al.
J. Pharmacol. Exp. Ther. 2001;298:565-580.
ABSTRACT
| FULL TEXT
Effects of chronic tramadol on pre- and post-synaptic measures of monoamine function
Hopwood et al.
J Psychopharmacol 2001;15:147-153.
ABSTRACT
Effects of rapid tryptophan depletion on brain 5-HT2 receptors: a PET study
YATHAM et al.
Br. J. Psychiatry 2001;178:448-453.
ABSTRACT
| FULL TEXT
The Effect of Paroxetine on 5-HT2A Receptors in Depression: An [18F]Setoperone PET Imaging Study
Meyer et al.
Am. J. Psychiatry 2001;158:78-85.
ABSTRACT
| FULL TEXT
Brain Serotonin2 Receptors in Major Depression: A Positron Emission Tomography Study
Yatham et al.
Arch Gen Psychiatry 2000;57:850-858.
ABSTRACT
| FULL TEXT
Decreased Serotonin 2A Receptor Densities in Neuroleptic-Naive Patients With Schizophrenia: A PET Study Using [18F]Setoperone
Ngan et al.
Am. J. Psychiatry 2000;157:1016-1018.
ABSTRACT
| FULL TEXT
|
